ClinicalTrials.gg
Not yet recruitingNCT07658469Updated Jun 22, 2026

Moderate-Intensity Aerobic Calisthenics for Rural Elderly With Motoric Cognitive Risk Syndrome

An interventional study of moderate-intensity aerobic exercise and Routine Care in Cognition Disorders and Aged, sponsored by Fujian Provincial Hospital. Not yet recruiting at 1 site in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Fujian Provincial Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Cognition Disorders with a site in China — 11 open to participants now, 11 under way, none of them phase 3. Cognition Disorders · China.

Planned enrollment
7th of 15
106 · median 94
Started
2026
with 4 others
No phase
10 of 23
9 open now
Primary completion
2026-07
later than 3 of 10 live
Registered
23rd of 23
by date
Lead sponsor
1 of 23
Fujian Provincial Hospital

Among the 23 studies in Cognition Disorders with a site in China, this one is the 7th largest by planned enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2026, is one of 10 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 23rd registered.

Cognition Disorders

399 studies on the registry are indexed under Cognition Disorders; 72 are open to participants now.

Browse Cognition Disorders studies →

Open to participants now

11 of the 23 studies in Cognition Disorders with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Cognition Disorders studies recruiting now, 20 (43%) set no upper age limit and 11 (24%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Cognition Disorders with a site in China, or all of them as a file.
02

Study summary

The aging of China's rural population is severe, with both the prevalence and mortality rates of dementia higher in rural areas than in urban areas. Motor Cognitive Risk Syndrome (MCR), as a novel pre-dementia syndrome characterized by both subjective cognitive decline and slow gait, represents a "golden window of opportunity" for the early prevention and treatment of dementia. Currently, there is no specific pharmacological treatment for MCR; non-pharmacological interventions, particularly exercise interventions, are key strategies. Moderate-intensity aerobic calisthenics, which integrates music, dance, and gymnastic elements, is economical, simple, highly engaging, safe, and has demonstrated potential for improving both cognitive and gait function, making it especially suitable for promotion in resource-limited rural settings. However, there is a lack of systematic, theory-guided exercise intervention protocols and effectiveness validation for rural older adults with MCR. Therefore, this study aims to develop and validate a moderate-intensity aerobic calisthenics intervention protocol tailored to this population.

Read the detailed description

Motor Cognitive Risk Syndrome (MCR), first defined by Verghese et al. in 2013, refers to the coexistence of subjective cognitive decline and slow gait in older adults without dementia or movement disorders, representing a novel pre-dementia syndrome situated between normal aging and dementia. The global prevalence of MCR is 9.0% (range: 2.4%-33.3%) , and the prevalence among Chinese older adults ranges from 4.00% to 13.85% , with higher rates in rural than urban areas-reaching as high as 16.7% in rural Anhui Province. MCR significantly increases the risk of dementia (three-fold) and particularly vascular dementia (12-fold) , and also elevates the incidence of falls, disability, and mortality. Cohort studies have shown that 22.1% of individuals with MCR progress to dementia, 57.5% remain in the MCR state, and 20.3% revert to normal cognition. This reversibility suggests that MCR represents a critical window for the ultra-early prevention and treatment of dementia.

Moderate-intensity aerobic calisthenics, which integrates music, dance, and gymnastic elements, is a form of moderate-intensity aerobic exercise. Evidence indicates that it effectively improves cognitive and physical function in older adults, exerts superior cognitive benefits compared to other exercise types, and reduces loneliness and depressive symptoms. The participation rate in physical exercise among older adults in rural China is only 33.9%-48.29%, limited by objective constraints such as lack of facilities and equipment, and monotonous forms of exercise. Aerobic calisthenics, characterized by its economy, simplicity, high appeal, and safety, is well-suited for promotion in rural areas. However, no studies to date have reported the application effects of this intervention in the MCR population, and thus investigating its intervention value in rural older adults with MCR holds significant research importance.

03

Conditions studied

  • Cognition Disorders
  • Aged

Browse trials for

Keywords

  • MCR
  • Motoric Cognitive Risk Syndrome
  • moderate-intensity aerobic exercise
  • rural areas
  • Aged
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥60 years;

    • Meeting the diagnostic criteria for Motor Cognitive Risk Syndrome (MCR);

      • Clear consciousness and ability to communicate clearly;

        • Permanent residents of rural areas in nine prefecture-level cities of Fujian Province (with an annual residence of ≥9 months) and no plan to relocate within the next year; -⑤ Willing to voluntarily participate and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Presence of severe mental disorders, history of stroke, Parkinson's disease, or severe visual/auditory impairments;

    • Physical disability that prevents independent walking;

      • Comorbid severe systemic diseases, such as cardiopulmonary conditions; -④ Regular exercise habits within the past 6 months (≥30 minutes/day, ≥3 days/week) or a long-term history of exercise; -⑤ Current participation in other interventional studies.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    Moderate-intensity aerobic exercise

    The group was intervened with a moderate-intensity aerobic exercise program developed by the research team.

    Other: moderate-intensity aerobic exercise

  • Experimental
    Routine Care

    This group of elderly people maintained their daily routines and received health education.

    Other: Routine Care

Interventions

  • Othermoderate-intensity aerobic exercise

    Based on routine health education, the intervention group receives a 12-week moderate-intensity aerobic exercise intervention (Jiamusi Happy Dance Steps) lasting 60 minutes per session, three times per week, delivered in a group setting, followed by a 12-week follow-up period.

  • OtherRoutine Care

    While maintaining daily living habits unchanged, provide knowledge related to health education for Motor Cognitive Risk Syndrome (MCR) and receive the MCR health education manual.

06

What researchers measure

Primary outcomes

  1. Montreal Cognitive Assessment Basic

    The MoCA-B was jointly developed by the Montreal Cognitive Assessment Clinic and Research Institute in Canada, in collaboration with the Prince Mahidol Award Foundation of Thailand and the Faculty of Medicine at Chulalongkorn University. It has a total score of 30 points and encompasses eight cognitive domains: executive function, language, orientation, calculation, abstract thinking, memory, visual perception, and attention, with higher scores indicating better cognitive function. The cutoff values are as follows: for years of education ≤6 years, MoCA-B ≥20; for 6 years \< years of education ≤12 years, MoCA-B ≥23; and for years of education \>12 years, MoCA-B ≥25. The scale correctly identifies cognitively normal participants with a specificity of 86%, and demonstrates a sensitivity of 81% for detecting cognitive impairment. The Cronbach's α coefficient of the scale is 0.807, and the criterion valid

    Time frame: The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.

  2. Walking speed

    The timed walking test was used to measure gait speed. The required equipment included a tape measure and a stopwatch. The specific procedure was as follows: First, a straight 6-meter course was measured using the tape measure, and the middle 4-meter segment was marked. The participant stood at the starting point. Then, upon the tester's command "Start," the participant walked at their normal pace to the endpoint. The time taken to cover the middle 4 meters was recorded using the same stopwatch. This was performed twice. Finally, gait speed was calculated using the formula speed = distance / time, with the average time of the two trials used for calculation.

    Time frame: The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.

Secondary outcomes

  1. Subjective Cognitive Decline-questionnaire 9

    The SCD-Q9 was adapted and revised into Chinese by Hao Lixiao et al. It encompasses two dimensions: global memory ability with time comparison, and activities of daily living. It primarily assesses memory, recall ability, language ability, attention, orientation, and other domains. The questionnaire consists of 9 items. The scoring reference criteria for item responses are as follows: "Yes" = 1 point, "No" = 0 points, "Often" = 1 point, "Occasionally" = 0.5 points. The total score ranges from 0 to 9 points, with higher scores indicating a greater likelihood of cognitive impairment. A score of ≥5 points suggests the possible presence of potential memory impairment.

    Time frame: The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.

  2. short physical performance battery

    The Short Physical Performance Battery (SPPB), developed by the National Institute on Aging (NIH), objectively assesses balance, lower limb strength, and physical function in older adults. Originally designed to predict disability, institutionalization, or mortality, it is now widely used for frailty, fall risk, and disease-related functional impairment. The SPPB includes three tests: balance, 4-meter gait speed, and five-repetition sit-to-stand, each scored 0-4, total 0-12 (higher = better function). Scores 0-3: severe mobility limitation with daily living difficulties; 4-6: mild limitation, needing assistance or aids; 7-9: normal mobility, independent in daily activities; 10-12: excellent mobility, robust and strong.

    Time frame: The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.

  3. Handgrip strength

    A electronic hand dynamometer (CAMRY, USA) was used to assess the upper limb muscle strength of the participants. Before measurement, the staff adjusted the dynamometer to zero. During the test, the participant stood in a natural posture with both arms hanging naturally at the sides. The dynamometer was kept as suspended as possible without touching the body, while maintaining the device stable. The participant was instructed to relax and then squeeze the dynamometer forcefully with the dominant hand three times (with an interval of \>15 seconds between each attempt). The maximum value among the three attempts was recorded as the grip strength.

    Time frame: The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.

  4. Body fat

    Body composition was assessed using bioelectrical impedance analysis (BIA) with an InBody H20N body fat scale, primarily measuring muscle and fat-related parameters. Before testing, participants wore light clothing without metal accessories and removed metal items such as watches, rings, and necklaces. During testing, participants stood barefoot on the metal electrode plates with feet shoulder-width apart, ensuring close contact of heels and forefeet with the plates. They held the handles on both sides with arms hanging naturally, hands dry and not touching the trunk. The operator initiated the measurement, during which participants remained still, silent, and motionless. The measurement lasted 1-2 minutes, and the device introduced a low-intensity electrical current to determine bioelectrical impedance parameters and estimate body composition.

    Time frame: The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.

  5. 12-Item Short-Form Health Survey

    The SF-12, a shortened version of the 36-Item Short-Form Health Survey (SF-36), assesses health-related quality of life. It retains the eight dimensions of the SF-36 with 12 items, covering general health (GH), physical functioning (PF), role physical (RP), bodily pain (BP), role emotional (RE), mental health (MH), vitality (VT), and social functioning (SF). The first four dimensions evaluate physical component summary (PCS), and the latter four evaluate mental component summary (MCS). The total score ranges from 0 to 100, with higher scores indicating better quality of life. Xiao Huimin et al. demonstrated good reliability and validity of the SF-12 among Chinese older adults.

    Time frame: The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.

  6. Patient Health Questionnaire-9

    The 9-item Patient Health Questionnaire (PHQ-9) assesses depressive symptom severity over the past two weeks. Each item is rated on a 4-point scale (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day), with a total score ranging from 0 to 27 (higher scores indicate greater depression severity). Cutoff scores: 0-4 = no depression; 5-9 = possible mild depression; 10-14 = moderate depression risk; ≥15 = severe depressive symptoms. The scale has good internal consistency (Cronbach's α = 0.894).

    Time frame: The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.

  7. Generalized Anxiety Disorder-7 item

    The 7-item Generalized Anxiety Disorder scale (GAD-7) assesses the severity of anxiety symptoms over the past two weeks. Each item is rated on a 4-point scale (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day), with a total score ranging from 0 to 21 (higher scores indicate greater anxiety severity). Cutoff scores: 0-4 = no anxiety; 5-9 = mild anxiety; 10-14 = moderate anxiety; ≥15 = severe anxiety. The scale has good internal consistency (Cronbach's α = 0.840) and demonstrates good reliability and validity in the Chinese population.

    Time frame: The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.

  8. World Health Organization Well-being Index

    The WHO-5 Well-Being Index, developed by Bech and revised by the WHO Collaborating Centre for Research in Mental Health, assesses subjective well-being over the past two weeks. The scale consists of 5 items, each rated on a 6-point scale (0 = none, 1 = a little of the time, 2 = less than half the time, 3 = more than half the time, 4 = most of the time, 5 = all the time). The raw sum is multiplied by 4 to obtain a standardized total score ranging from 0 to 100, with higher scores indicating better well-being. The scale has good internal consistency (Cronbach's α = 0.86) . A score below 50 indicates reduced well-being \[144\]. In this study, well-being is categorized as high (≥70), moderate (50-70), and low (≤50).

    Time frame: The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.

  9. The Theory of Planned Behavior Questionnaire (Exercise Version)

    The Theory of Planned Behavior Questionnaire, developed by Icek Ajzen, consists of 12 items across four dimensions: behavioral attitude, subjective norm, perceived behavioral control, and behavioral intention. It is used to measure the social cognitive variables of the theory of planned behavior. The target behavior in this questionnaire refers to the exercise goal set for rural older adults with Motor Cognitive Risk Syndrome (i.e., participating in at least 150 minutes of moderate-intensity aerobic exercise per week). Items are rated on a 7-point Likert scale, ranging from "strongly disagree" to "strongly agree," with scores from 1 to 7. Higher scores indicate greater levels of agreement.

    Time frame: The intervention was carried out in August 2026, and the assessment period was 0,3,6 months.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jul 2026, 0 months later.

Of 88 non-industry interventional studies with no phase under Cognition Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 55. This study's planned 0 months is below that.

Counting every sponsor, half of 93 studies reached it within 34 months; a quarter within 16 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2026
First posted
Jun 22, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07658469
Lead sponsor
Fujian Provincial Hospital
Responsible party
Yuanjiao Yan (Study Director, Fujian Medical University) — Principal investigator
First posted
Jun 22, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Jul 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Tuantuan Guo
Contact
390977233@qq.com
+86 159 5989 7344

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion